| Queencell (Anterogen Co. Ltd.) | South Korea (2010) | Subcutaneous tissue defects | Autologous human AT-MSC |
| Cellgram-AMI (Pharmicell Co. Ltd.) | South Korea (2011) | Acute myocardial infarction | Autologous human BM-MSC |
| Cartistem (Medipost Co. Ltd.) | South Korea (2012) | Knee articular cartilage defects | Allogeneic human UC-MSC |
| Cupistem (Anterogen Co. Ltd.) | South Korea (2012) | Crohn’s fistula | Autologous human BM-MSC |
| Prochymal, remestemcel-L (Osiris Therapeutics Inc., Mesoblast Ltd.) | Canada (2012)
New Zealand (2012) | Graft versus host disease | Allogeneic human BM-MSC |
| Neuronata-R (Corestem Inc.) | South Korea (2014) | Amyotrophic lateral sclerosis | Autologous human BM-MSC |
| Temcell HS (JCR Pharmaceuticals) | Japan (2015) | Graft versus host disease | Allogeneic human BM-MSC |
| Stempeucel (Stempeutics Research PVT) | India (2016) | Critical limb ischemia | Allogeneic human BM-MSC |
| Alofisel (TiGenix NV/Takeda) | Europe (2018) | Complex perianal fistulas in Crohn’s disease | Allogeneic human AT-MSC |
| Stemirac (Nipro Corp) | Japan (2018) | Spinal cord injury | Autologous human BM-MSC |